相关实验视频
Updated: Sep 11, 2025
08:05
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
40.5K
穆尔贝罗胺A通过抑制Th2反应和氧化应激来改善小鼠过敏气道炎症
Chian-Jiun Liou1,2, Shu-Ju Wu3,4, Shu-Chen Cheng5,6
1Department of Nursing, Division of Basic Medical Sciences, Center for Drug Research and Development, Chang Gung University of Science and Technology, Taoyuan, 33303, Taiwan.
Inflammopharmacology
|August 18, 2025
概括
Mulberroside A是一种来自木的化合物,有效地减少了喘模型中的呼吸道炎症和高反应性. 它还在气管细胞中表现出抗炎和抗氧化作用,显示出喘治疗的潜力.
科学领域:
- 自然产品化学 自然产品化学
- 免疫学 免疫学 免疫学
- 呼吸系统医学 呼吸系统医学
背景情况:
- Mulberroside A,来自Morus alba L. (木果),在肌肉细胞中表现出抗炎特性.
- 对于呼吸道炎症和喘中的过度反应,Mulberroside A的治疗潜力仍然未被探索.
研究的目的:
- 在喘小鼠模型中研究Mulberroside A在改善呼吸道炎症和高反应性方面的疗效.
- 评估Mulberroside A对气管上皮细胞的抗炎和抗氧化作用.
主要方法:
- 临床前研究使用卵素 (OVA) 或OVA/脂聚糖 (LPS) 敏感的BALB/c小鼠接受Mulberroside A (10或20 mg/kg) 治疗.
- 在体外研究评估Mulberroside A对炎症性气管上皮细胞的影响,包括活性氧物种 (ROS) 生产和细胞因子表达.
- 分析炎症细胞透,杯状细胞增生,细胞因子 (Th2相关) 和粘附分子表达 (ICAM-1).
主要成果:
- 在OVA诱导的喘模型中,Mulberroside A治疗减弱了呼吸道过度反应,炎症细胞透和杯状细胞过度增生.
- 它减少了氧化应激和Th2相关的细胞因子表达,缓解了呼吸道炎症.
- 在体外,Mulberroside A通过抑制细胞间粘附分子-1 (ICAM-1) 来降低ROS的产生,促炎性细胞因子,eotaxin和单细胞附着.
- 在OVA/LPS模型中,Mulberroside A显著降低了中性粒细胞透和炎症性细胞因子水平.
结论:
- 穆尔贝罗胺A在缓解呼吸道炎症和与喘相关的过敏反应方面显示出显著的潜力.
- 其在体内和体外模型中观察到的抗炎和抗氧化特性支持其在喘管理中的治疗前景.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
453
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
453
01:20Asthma: Pathogenesis and Management
581
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
581
01:19Antiasthma Drugs: Leukotriene Modifiers
463
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
463
01:17Drugs Used in Lower Respiratory Disorders: Overview
578
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
578